NRX Pharmaceuticals, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Wilmington, DE. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1 million and a loss of $29 million (its filed statements).
Pre-revenue companyPharmaceutical PreparationsWilmington, DEfilings since 20176 of 9 filed, 3 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.4 out of ten, 6 of 9 metrics filed and 3 estimated: past 5.6 out of ten, present 2.2 out of ten, future 3.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 0.0 out of ten. 23 warning events since 2017; the latest 2026-01-16. 0th percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.8 out of ten. 3 filed years; profitable in 0 of 3. 59th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 9.0 out of ten. CrossAssetData estimate 9.0/10, confidence 35 of 100 (one part). 90th percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 1.9 out of ten. Leverage 223%: owes 223¢ per asset dollar. 19th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 2.5 out of ten. bottom 25% of 314 in its family; net margin -1980.8%. 25th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 2.4 out of ten. bottom 24% of 315 in its family for leadership. 24th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 5.0 out of ten. top 50% of 272 in its family for room to expand. 50th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 0.8 out of ten. CrossAssetData estimate 0.8/10, confidence 35 of 100 (one part). 8th percentile among 324 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Expectations vs reality (future): 5.3 out of ten. CrossAssetData estimate 5.3/10, confidence 20 of 100 (family median). 50th percentile among 235 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
The filing record
Newest annual report: Form 10-K filed 2026-03-23 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-14 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-17 (on EDGAR). Newest filing: Form 8-K, 2026-10-05. Filings on record since 2017. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Therapy 70%, Procedures 30%. As tagged in its annual report (Form 10-K, filed 2026-03-23).
Who runs it
Javitt, Jonathan C (Chairman and Chief Scientist); Casper, Joseph Michael (Chief Operating Officer); Flynn, Patrick John (director); Hurvitz, Chaim (director); Mcbride, Dennis (director). 5 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.